Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
G has been shown to participate in various MT
2023-12-02

Gβγ has been shown to participate in various MT-dependent processes such as cell growth and differentiation [15,[21], [22], [23], [24], [25], [26]]. G-protein β-subunit anti-sense oligonucleotides have been shown to inhibit cell proliferation and cause disorganization of the mitotic spindle in mamma
-
br Hypoadiponectinemia in metabolic syndrome APN belongs str
2023-12-02

Hypoadiponectinemia in metabolic syndrome APN belongs structurally to the complement 1q family and is found at high concentrations (>0.01% of total protein) in the serum of healthy individuals [6]. Given the abundance of APN in plasma, it is assumed that alterations in plasma levels of APN might
-
br Conclusions The present data
2023-12-01

Conclusions The present data suggest that homeostatic balance of the cortical/hippocampal adenosinergic tone is necessary for normal working memory function and any deviation appears to impair performance – either as a consequence of A2AR under-activation when adenosine levels are reduced or due
-
Finally we show that the optimal corporate tax rate is
2023-12-01

Finally, we show that the optimal corporate tax rate is strictly positive, balancing the increase in tax revenues against the loss in consumer surplus due to higher prices and fewer firms (products). This result is related to the well-known “excessive entry theorem” that shows, for a large class of
-
br ARIs in the prevention of prostate cancer
2023-12-01

5ARIs in the prevention of prostate cancer Prostate cancer continues to be a leading cause of male deaths worldwide. In 2009, it was estimated there would be 192,280 new cases of prostate cancer with a predicted 27,360 deaths [25]. Because androgens, and specifically DHT, play a large role in bot
-
The compounds containing beryllium act as strong
2023-12-01

The compounds containing beryllium act as strong Lewis acids because of electron deficiency of the Be Phenformin receptor []. Interactions of X-Be-Y compounds with different Lewis bases have been studied by Yanez and co-workers [], extensively. Recently, they proposed a class of extremely strong bi
-
These anatomical studies were followed by the first function
2023-12-01

These anatomical studies were followed by the first functional MRI studies of auditory processing in songbirds that were performed in starlings (Van Meir et al., 2005; De Groof et al., 2017; De Groof et al., 2013b) and in zebra finches (Boumans et al., 2008a; Boumans et al., 2007; Boumans et al., 20
-
Besides Arg overexpression our data revealed that AGEs could
2023-12-01

Besides Arg2 overexpression, our data revealed that AGEs could decrease eNOS mRNA levels, which is considered a significant cause for attenuated NO production and vasodilation. It was found recently that AGEs significantly reduce eNOS expression levels and NO bioavailability in human carotid artery
-
The mitochondrial protein AIF was the first
2023-12-01

The mitochondrial protein AIF was the first caspase-independent death effector. AIF can induce caspase-independent chromatin condensation and large-scale DNA fragmentation to approximately 50 KB. AIF that is released to cytoplasm can mediate apoptosis when special extracellular signals trigger the o
-
Sorafenib was the first small RTK inhibitor drug to
2023-12-01

Sorafenib was the first small RTK inhibitor drug to be developed and was initially approved against renal cell carcinoma, then against hepatocellular carcinoma (HCC) and more recently for differentiated thyroid treatment [111]. Sunitinib soon followed, being approved for gastrointestinal stromal tum
-
In AD and possibly other forms of dementia it
2023-11-30

In AD, and possibly other forms of dementia, it has been suggested that tau mislocalization to dendritic spines anticipates neurodegeneration [48]. Accumulation of hyperphosphorylated tau in dendritic spies would cause a derangement of synaptic function, thereby impairing excitatory synaptic transmi
-
ISX 9 br Discussion The patient presented initially only wit
2023-11-30

Discussion The patient presented initially only with parietal symptoms in the form of acalculia, visuo-spatial deficits, and visuo-perceptual deficits and dressing apraxia. He also had simultognosia as early symptoms. Later when the disease progressed he had recent memory deficits and language in
-
The anorexic effect observed when AR
2023-11-30

The anorexic effect observed when AR231630 is infused into the VTA could be the result of the DA release inhibition, as previously described [11]. However, there is also a hedonic aspect in feeding that possibly involves dopaminergic mechanisms of reward. Helm et al. showed a functional link between
-
By promoting bundling and processive elongation of actin fil
2023-11-30

By promoting bundling and processive elongation of SB 203580 hydrochloride filaments and inhibiting association of capping protein with filament barbed ends, Ena/VASP family proteins contribute to the dynamics of lamellipodia and filopodia [41] and maintenance of focal adhesions and tight junctions
-
The first rationally designed dual mPGES LO inhibitor was
2023-11-30

The first rationally designed dual mPGES-1/5-LO inhibitor was reported in 2008 and represents a structural derivative of pirinixic mineralocorticoid receptor antagonists - a synthetic agonist of PPARα with lipid-lowering properties (Koeberle et al., 2008b). Further α-alkyl- and α-aryl-substituted d
16554 records 241/1104 page Previous Next First page 上5页 241242243244245 下5页 Last page